APA (7th ed.) Citation

H, B., D, B., LG, P., M, R., S, L., SS, R., . . . KJ, O. (2026). Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, OF1. https://doi.org/10.1158/1078-0432.CCR-25-0942

Chicago Style (17th ed.) Citation

H, Borghaei, et al. "Early Detriment Analysis of First-Line Nivolumab Plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2026: OF1. https://doi.org/10.1158/1078-0432.CCR-25-0942.

MLA (9th ed.) Citation

H, Borghaei, et al. "Early Detriment Analysis of First-Line Nivolumab Plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 2026, p. OF1, https://doi.org/10.1158/1078-0432.CCR-25-0942.